[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100416358":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":17,"centralContacts":18,"locations":17,"responsibleParty":29,"collaborators":17,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":37,"eligibilityCriteria":38,"healthyVolunteers":33,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":17,"studyType":45,"phases":46,"briefSummary":48,"conditions":49,"keywords":17,"overallStatus":52,"whyStopped":17,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":17},{"fullName":5,"class":6},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Immuno-inflammatory profile description in patients with ischemic stroke","OTHER","Patients will be evaluated for inflammatory biomarkers at inclusion, at 24-48 hours of reperfusion treatment , at 72 hours, at 7 days or at discharge if before D7, at discharge if after D7, at 3 months and at 1 year.The biomarkers will be measured using ELISA panels for inflammatory biomarkers",[13],"Other: Immuno-inflammatory profile description in patients with ischemic stroke",[15],{"type":10,"name":9,"description":11,"armGroupLabels":16,"otherNames":17},[9],null,[19,25],{"name":20,"role":21,"phone":22,"phoneExt":23,"email":24},"Benjamin MAIER, Professor, MD, PhD","CONTACT","01 48 03 65 56","+ 33","bmaier@for.paris",{"name":26,"role":21,"phone":27,"phoneExt":23,"email":28},"Amélie YAVCHITZ, MD, PhD","01 48 03 64 54","ayavchitz@for.paris",{"type":30,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100416358","immuno-inflammatory-profile-and-response-to-ischemic-stroke-reperfusion-therapies-immunostroke-100416358",false,"NCT04701619","Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)","Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies","IMMUNOSTROKE","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Presenting with an ACS for which reperfusion therapy is indicated according to European and North American recommendations (IV thrombolysis or mechanical thrombectomy or a combination of both)\n* Having received informed information about the study and having signed a consent form to participate in the study (if this is not possible: information and consent from a trusted person or family member if present; emergency inclusion if absent)\n* Affiliated with or beneficiary of a social security system\n\nExclusion Criteria:\n\n* Contraindication to performing a brain MRI (claustrophobia, pacemaker, or other implantable device contraindicating the performance of an MRI)\n* Intracranial hemorrhage associated with AIC on initial imaging\n\nImmunosuppressive treatment or corticosteroid therapy at patient admission\n\n* Pre-existing neurological disability limiting neurological assessment at 3 months (mRS\\>2 at admission)\n* Known and diagnosed dementia pre-existing at the time of the AIC\n* Absolute or relative contraindication to the injection of gadolinium (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \\\u003C15mL\u002Fmin, pregnant or breastfeeding women)\n* Patient treated by another institution and referred solely for mechanical thrombectomy\n* Patient benefiting from legal protection measures","ALL","18 Years","90 Years",{"count":43,"type":44},300,"ESTIMATED","INTERVENTIONAL",[47],"NA","IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different parameters over time. Post-hoc analyses will make it possible to correlate the immuno-inflammatory and thrombo-inflammatory profiles and their evolution with the clinical outcome in terms of post-AIC functional and cognitive disability.",[50,51],"Stroke","Ischemic Stroke","NOT_YET_RECRUITING","2026-01-16",{"date":55,"type":56},"2026-01-20","ACTUAL",{"date":58,"type":44},"2026-09-15",{"date":60,"type":44},"2028-05-15",{"name":5,"class":6}]